Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of autologous NY-ESO-1/LAGE-1a TCR T cells with or without pembrolizumab in advanced NSCLC
2018-003949-42Phase 2Unknown
- Sponsor
- GSK
- Start
- Jul 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of letetresgene autoleucel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by GSK. Primary endpoint: Safety and tolerability (adverse events). Status: unknown.
02
Drugs
letetresgene autoleucel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003949-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003949-42.